Listen: Relitigating Vioxx, industry growing pains, & how biotech VC works
Were we too hard on Vioxx? Are you still a disruptor if you have a lobbying budget? And how does venture capital work, exactly?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology industry is growing up and getting corporate. Finally, health care journalist Maggie Fox dials in to explain her deep dive on venture capital in biotech.
Read Original Article: Listen: Relitigating Vioxx, industry growing pains, & how biotech VC works »
